These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1715 related articles for article (PubMed ID: 18847555)
1. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555 [TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969 [TBL] [Abstract][Full Text] [Related]
3. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021 [TBL] [Abstract][Full Text] [Related]
4. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Cox JT; Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506 [TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804 [TBL] [Abstract][Full Text] [Related]
7. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934 [TBL] [Abstract][Full Text] [Related]
8. Screening for cervical cancer: new alternatives and research. Lörincz AT Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031 [TBL] [Abstract][Full Text] [Related]
9. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Gilham C; Sargent A; Kitchener HC; Peto J Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027 [TBL] [Abstract][Full Text] [Related]
10. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869 [TBL] [Abstract][Full Text] [Related]
11. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739 [TBL] [Abstract][Full Text] [Related]
12. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion]. Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778 [TBL] [Abstract][Full Text] [Related]
14. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720 [TBL] [Abstract][Full Text] [Related]
16. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan. Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473 [TBL] [Abstract][Full Text] [Related]
18. [A study of cervical cancer screening algorithms]. Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481 [TBL] [Abstract][Full Text] [Related]
19. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840 [TBL] [Abstract][Full Text] [Related]